Market Size of Malaysia Diabetes Care Drugs Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 389.13 Million |
| Market Size (2029) | USD 423.21 Million |
| CAGR (2024 - 2029) | 3.10 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Malaysia Diabetes Drugs Market Analysis
The Malaysia Diabetes Care Drugs Market size is estimated at USD 389.13 million in 2024, and is expected to reach USD 423.21 million by 2029, growing at a CAGR of 3.10% during the forecast period (2024-2029).
Malaysia's Ministry of Health reported 5,809 new COVID-19 cases in 24 hours, comprising 5,782 locally infected and 27 imported cases, increasing the national total to 2,541,147. So far, about 78.4 percent of the Malaysian population has gotten at least one dose of the COVID-19 vaccine, with 75.9 percent completely vaccinated. According to the Health Ministry, four out of every ten patients who died from COVID-19 in Malaysia this year had diabetes. Diabetes affects one in every five Malaysians, or around 3.9 million persons aged 18 and up.
The number of young diabetics is increasing. Diabetes is becoming more common in younger individuals, with the number of diabetics aged 18 to 40 more than tripling in the last 15 years. The growing population of diabetics means a greater burden of the illness and its consequences, including heart disease, stroke, blindness, chronic kidney disease, and lower limb amputation.
In reality, underlying comorbidities account for most coronavirus mortality in Malaysia, with diabetes and hypertension leading the list.
In terms of medicines, the insulin category commands a sizable market share. Over 100 million people worldwide use insulin, including all persons with Type 1 diabetes and 10% to 25% of people with Type 2 diabetes. Insulin production is extremely sophisticated, and only a few insulin manufacturers are on the market. As a result, there is fierce rivalry among these producers, who continually strive to satisfy patients' demands by providing the highest-quality insulin.
